Skip to main content
RENALYTIX PLC logo

RENALYTIX PLC — Investor Relations & Filings

Ticker · RENX ISIN · GB00BYWL4Y04 LEI · 213800NTOH3FK3WER551 IL Human health and social work activities
Open in API
Filings indexed 444 across all filing types
Latest filing 2025-07-17 Board/Management Inform…
Country GB United Kingdom
Listing IL RENX

About RENALYTIX PLC

https://renalytix.com/

Renalytix is a diagnostics company that develops artificial intelligence-enabled solutions for the clinical management of kidney disease. Its flagship product, KidneyIntelX.dkd™, is an FDA-authorized blood test for adults with type 2 diabetes and early-stage chronic kidney disease. The test utilizes a proprietary bioprognostic™ methodology to analyze biomarkers and clinical data, predicting the risk of a progressive decline in kidney function over a five-year period. This risk assessment enables clinicians to identify high-risk patients and implement targeted, guideline-recommended treatments to slow disease progression and improve outcomes.

Recent filings

Filing Released Lang Actions
Change of Adviser
Board/Management Information Classification · 99% confidence The document is a short announcement (4317 characters) released via RNS (London Stock Exchange news service). The primary content is the announcement of a 'Change of Adviser,' specifically the appointment of SP Angel Corporate Finance LLP as the Nominated Adviser and Joint Corporate Broker. This type of corporate action announcement, which is brief and relates to administrative/advisory changes rather than financial results (ER, IR) or shareholder votes (DVA), fits best under the general regulatory announcement category, RNS, as it is a mandatory disclosure to the market via the official news service.
2025-07-17 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains fields related to voting rights, share thresholds, and notification dates (e.g., 'Date on which the threshold was crossed or reached: 25 June 2025'). This structure is characteristic of regulatory filings concerning changes in significant share ownership. The RNS Number and reference to the FCA confirm its regulatory nature. This directly matches the definition for Major Shareholding Notification (MRQ).
2025-06-27 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains fields related to voting rights, share acquisition/disposal, and notification dates (26 June 2025). This structure is characteristic of regulatory filings concerning changes in significant share ownership thresholds. The presence of 'RNS Number' and the reference to the FCA (Financial Conduct Authority) confirms it is a regulatory disclosure. The specific content—reporting a holding crossing the 5% threshold by UBS Group AG—directly matches the definition of a Major Shareholding Notification. Therefore, the correct code is MRQ.
2025-06-26 English
kidneyintelX.dkd data presented at ERA Congress
Regulatory Filings Classification · 98% confidence The document is a press release distributed via the Regulatory News Service (RNS) by Renalytix plc. It announces the presentation of clinical data regarding their product 'kidneyintelX.dkd' at the European Renal Association Congress. It does not constitute a financial report, audit, or regulatory filing in the sense of a mandatory disclosure, but rather a corporate news update regarding clinical research and product validation. As it is a general regulatory announcement that does not fit into specific categories like earnings or M&A, it is classified as a Regulatory Filing (RNS).
2025-06-17 English
Growing collaboration with NYKHM
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated 03 June 2025. It contains a header stating 'THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (MAR)'. The content describes a business development: a collaboration between Renalytix plc and New York Kidney & Hypertension Medicine (NYKHM) to expand access to a diagnostic test. This is a typical structure for a regulatory news service announcement disseminated via RNS (Regulatory News Service) of the London Stock Exchange. Since it is a general announcement of a business event that doesn't fit specific categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), and it is clearly distributed through the RNS system, the most appropriate classification is Regulatory Filings (RNS). It is not a full report (10-K, IR) or a mere announcement of a report (RPA).
2025-06-03 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is titled 'TR-1: Standard form for notification of major holdings' and is filed via 'RNS Number : 8431K' on '30 May 2025'. This form is used to report changes in significant share ownership, specifically detailing when a shareholder's holding crosses or falls below a notification threshold (in this case, UBS Group AG's holding fell below 5%). This directly corresponds to the definition of a Major Shareholding Notification, which is classified as 'MRQ' in the provided schema.
2025-05-30 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.